{"title":"PP143 Redox-modulatory and MET-inhibitory triad: Synergistic cytotoxicity of L-cysteine, NAC, and MET inhibition in cervical cancer cells","authors":"Yingqiu Xie , Aigerim Tassanbiyeva , Aruzhan Onggarbek","doi":"10.1016/j.esmoop.2025.105980","DOIUrl":"10.1016/j.esmoop.2025.105980","url":null,"abstract":"","PeriodicalId":11877,"journal":{"name":"ESMO Open","volume":"11 ","pages":"Article 105980"},"PeriodicalIF":8.3,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147394758","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-02-01Epub Date: 2026-02-28DOI: 10.1016/j.esmoop.2025.105986
Woo Kyun Bae , Hyun Jin Bang , Hye Kyung Lee , Myong-Suk Park , Misun Yun , Lothar Hennighausen , Priscilla A. Furth , Ik-Joo Chung , Sang-Hee Cho
{"title":"PP198 Lactic acid bacteria enhance antitumor immunity in bladder cancer via modulation of the tumor microenvironment","authors":"Woo Kyun Bae , Hyun Jin Bang , Hye Kyung Lee , Myong-Suk Park , Misun Yun , Lothar Hennighausen , Priscilla A. Furth , Ik-Joo Chung , Sang-Hee Cho","doi":"10.1016/j.esmoop.2025.105986","DOIUrl":"10.1016/j.esmoop.2025.105986","url":null,"abstract":"","PeriodicalId":11877,"journal":{"name":"ESMO Open","volume":"11 ","pages":"Article 105986"},"PeriodicalIF":8.3,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147413563","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"PP398 Improved cancer coping from a psych educational web-based intervention for advanced cancer survivors: A randomized controlled trial","authors":"Nurul Huda , Malissa Kay Shaw , Bayu Satria Wiratama , Eka Febriyanti","doi":"10.1016/j.esmoop.2025.106014","DOIUrl":"10.1016/j.esmoop.2025.106014","url":null,"abstract":"","PeriodicalId":11877,"journal":{"name":"ESMO Open","volume":"11 ","pages":"Article 106014"},"PeriodicalIF":8.3,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147414339","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-02-01Epub Date: 2026-02-28DOI: 10.1016/j.esmoop.2025.106002
Yantao Tian, Yujuan Jiang, Jinghua Chen
{"title":"PP301 The global and regional burden of early-onset gastric cancer in adolescents and adults aged 15–49 years (1990–2021): An analysis of incidence, mortality, and DALYs with projections to 2030","authors":"Yantao Tian, Yujuan Jiang, Jinghua Chen","doi":"10.1016/j.esmoop.2025.106002","DOIUrl":"10.1016/j.esmoop.2025.106002","url":null,"abstract":"","PeriodicalId":11877,"journal":{"name":"ESMO Open","volume":"11 ","pages":"Article 106002"},"PeriodicalIF":8.3,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147420524","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-02-01Epub Date: 2026-01-27DOI: 10.1016/j.esmoop.2025.106027
X. Le , S. Popat , J.V. Heymach , H. West , L. Zhang
Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs), alone or as part of combination regimens, remain the standard first-line treatment for patients with EGFR-mutation positive (EGFRm-positive) advanced non-small-cell lung cancer (NSCLC). Optimal therapy after development of resistance is not yet well established. In this review, we explore the latest clinical trial data summarizing potential treatment approaches designed to overcome acquired resistance to EGFR TKIs in EGFRm-positive advanced NSCLC. After progression while on EGFR TKIs, repeat biopsy should be strongly considered to detect histological transformation, for which platinum-based chemotherapy remains standard treatment. Identification of actionable resistance mutations may also inform a personalized approach for subsequent treatments, but current clinical data are not convincing enough to make this a clear standard of care. Several treatment approaches have shown improved progression-free survival or overall survival in patients with acquired EGFR TKI resistance. We review data for combinations with immune therapy, bispecific antibodies, and antibody–drug conjugates, including the activity of the combinations in patients with brain metastases. As more options become available, the role for shared physician–patient decision making regarding anticipated side-effects, treatment schedule, and efficacy becomes more important.
{"title":"Treatment options and considerations for acquired resistance in EGFR mutation-positive non-small-cell lung cancer","authors":"X. Le , S. Popat , J.V. Heymach , H. West , L. Zhang","doi":"10.1016/j.esmoop.2025.106027","DOIUrl":"10.1016/j.esmoop.2025.106027","url":null,"abstract":"<div><div>Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs), alone or as part of combination regimens, remain the standard first-line treatment for patients with <em>EGFR</em>-mutation positive (<em>EGFR</em>m-positive) advanced non-small-cell lung cancer (NSCLC). Optimal therapy after development of resistance is not yet well established. In this review, we explore the latest clinical trial data summarizing potential treatment approaches designed to overcome acquired resistance to EGFR TKIs in <em>EGFR</em>m-positive advanced NSCLC. After progression while on EGFR TKIs, repeat biopsy should be strongly considered to detect histological transformation, for which platinum-based chemotherapy remains standard treatment. Identification of actionable resistance mutations may also inform a personalized approach for subsequent treatments, but current clinical data are not convincing enough to make this a clear standard of care. Several treatment approaches have shown improved progression-free survival or overall survival in patients with acquired EGFR TKI resistance. We review data for combinations with immune therapy, bispecific antibodies, and antibody–drug conjugates, including the activity of the combinations in patients with brain metastases. As more options become available, the role for shared physician–patient decision making regarding anticipated side-effects, treatment schedule, and efficacy becomes more important.</div></div>","PeriodicalId":11877,"journal":{"name":"ESMO Open","volume":"11 2","pages":"Article 106027"},"PeriodicalIF":8.3,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146075310","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-02-01Epub Date: 2026-02-03DOI: 10.1016/j.esmoop.2025.106058
M. Mandalà , P. Rutkowski , R. Patuzzo , A. Maurichi , J. Placzke , P. Teterycz , F. Galli , M.P. Di Palma , E. Gambale , L. Romano , S. Costabile , P. Quaglino , P. Covarelli , G.M. Tomassini , S. Ribero , L. Stingeni , A. Sidoni , D. Massi , M. Santinami
Background
Melanoma has the highest risk of brain metastasis (BM) among common solid tumors. Data on risk factors of developing BM in stage II-III melanoma are scarce. We investigated the incidence, timing, and risk factors associated with BM development in stage II-III melanoma patients.
Patients and methods
We carried out a multicenter retrospective cohort study. Clinical and pathological data on consecutive melanoma patients diagnosed, treated, and followed up in four Italian and one Polish referral melanoma centers were retrieved. A conditional inference tree (CIT) was derived to stratify patients according to their risk of BM occurrence based on prognostic factors.
Results
Between 1998 and 2023, we identified 8992 patients, of whom 5021 had stage II-III disease and were included in the main outcome analysis. The incidence of BM in the whole population was 6.9% (344/5021 patients). The number of patients needed to detect one BM after the primary resection was 105 [95% confidence interval (CI) 79-142] in the first year, 40 (95% CI 33-49) in the second year, and 71 (95% CI 52-102) in the fifth year. At multivariable analysis, older patients {≥60 years versus <40 years [odds ratio (OR) 0.63, 95% CI 0.43-0.92, P = 0.0156)} and Breslow thickness (BT) >4 mm (versus <2 mm; OR 0.68, 95% CI 0.46-1.01, P = 0.0574) were associated with a lower risk of BM versus extracranial recurrence only, while male sex (OR 1.47, 95% CI 1.11-1.93, P = 0.0065) and ulceration (OR 1.33, 95% CI 1.00-1.76, P = 0.0499) were associated with a higher risk. According to CIT, the highest absolute risk (13.5%) was observed in patients with ulcerated melanoma, BT >4 mm, and a positive sentinel lymph node biopsy.
Conclusions
Our study identifies stage II-III melanoma patients at a high risk of BM and provides clinically useful information for tailoring follow-up.
背景：黑色素瘤是常见实体肿瘤中脑转移风险最高的肿瘤。II-III期黑色素瘤发生脑转移的危险因素资料很少。我们调查了II-III期黑色素瘤患者发生脑转移的发生率、时间和危险因素。患者和方法：我们进行了一项多中心回顾性队列研究。检索了四个意大利和一个波兰转诊黑色素瘤中心诊断、治疗和随访的连续黑色素瘤患者的临床和病理数据。根据预后因素，导出条件推断树（CIT），根据患者发生脑转移的风险对患者进行分层。结果：1998年至2023年间，我们确定了8992例患者，其中5021例为II-III期疾病，并纳入主要结局分析。人群中BM的发生率为6.9%（344/5021例）。首次切除后需要检测1个脑转移瘤的患者数量在第一年为105例[95%可信区间（CI） 79-142]，第二年为40例（95% CI 33-49），第五年为71例（95% CI 52-102）。在多变量分析中，老年患者{≥60岁vs . 4mm (vs . 4mm)，前哨淋巴结活检阳性。结论：我们的研究确定了II-III期黑色素瘤患者BM的高风险，并为定制随访提供了临床有用的信息。
{"title":"Incidence and risk factors of brain metastases in radically resected melanoma patients: a large international cohort study","authors":"M. Mandalà , P. Rutkowski , R. Patuzzo , A. Maurichi , J. Placzke , P. Teterycz , F. Galli , M.P. Di Palma , E. Gambale , L. Romano , S. Costabile , P. Quaglino , P. Covarelli , G.M. Tomassini , S. Ribero , L. Stingeni , A. Sidoni , D. Massi , M. Santinami","doi":"10.1016/j.esmoop.2025.106058","DOIUrl":"10.1016/j.esmoop.2025.106058","url":null,"abstract":"<div><h3>Background</h3><div>Melanoma has the highest risk of brain metastasis (BM) among common solid tumors. Data on risk factors of developing BM in stage II-III melanoma are scarce. We investigated the incidence, timing, and risk factors associated with BM development in stage II-III melanoma patients.</div></div><div><h3>Patients and methods</h3><div>We carried out a multicenter retrospective cohort study. Clinical and pathological data on consecutive melanoma patients diagnosed, treated, and followed up in four Italian and one Polish referral melanoma centers were retrieved. A conditional inference tree (CIT) was derived to stratify patients according to their risk of BM occurrence based on prognostic factors.</div></div><div><h3>Results</h3><div>Between 1998 and 2023, we identified 8992 patients, of whom 5021 had stage II-III disease and were included in the main outcome analysis. The incidence of BM in the whole population was 6.9% (344/5021 patients). The number of patients needed to detect one BM after the primary resection was 105 [95% confidence interval (CI) 79-142] in the first year, 40 (95% CI 33-49) in the second year, and 71 (95% CI 52-102) in the fifth year. At multivariable analysis, older patients {≥60 years versus <40 years [odds ratio (OR) 0.63, 95% CI 0.43-0.92, <em>P</em> = 0.0156)} and Breslow thickness (BT) >4 mm (versus <u><</u>2 mm; OR 0.68, 95% CI 0.46-1.01, <em>P</em> = 0.0574) were associated with a lower risk of BM versus extracranial recurrence only, while male sex (OR 1.47, 95% CI 1.11-1.93, <em>P</em> = 0.0065) and ulceration (OR 1.33, 95% CI 1.00-1.76, <em>P</em> = 0.0499) were associated with a higher risk. According to CIT, the highest absolute risk (13.5%) was observed in patients with ulcerated melanoma, BT >4 mm, and a positive sentinel lymph node biopsy.</div></div><div><h3>Conclusions</h3><div>Our study identifies stage II-III melanoma patients at a high risk of BM and provides clinically useful information for tailoring follow-up.</div></div>","PeriodicalId":11877,"journal":{"name":"ESMO Open","volume":"11 2","pages":"Article 106058"},"PeriodicalIF":8.3,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146112583","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"PP124 An alternative approach to combat colorectal cancer metastasis by neutrophil extracellular traps (NETs) using galangal-based synthetic compound (PK3)","authors":"Podchanart Wanitchakool , Mashima Naksawat , Lalida Sirianan , Pakit Kambunma","doi":"10.1016/j.esmoop.2025.105972","DOIUrl":"10.1016/j.esmoop.2025.105972","url":null,"abstract":"","PeriodicalId":11877,"journal":{"name":"ESMO Open","volume":"11 ","pages":"Article 105972"},"PeriodicalIF":8.3,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147412603","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-02-01Epub Date: 2026-02-28DOI: 10.1016/j.esmoop.2025.105985
Li-Jen Cheng , Eo Jin Kim , Kyungah Park , David Nimke , Eunjee Cho , Mia Unsworth , Maria Walley , Amber Simpson
{"title":"PP190 Real-world evaluation of patient characteristics, and treatment patterns in locally advanced or metastatic urothelial cancer following approval of maintenance therapy in South Korea","authors":"Li-Jen Cheng , Eo Jin Kim , Kyungah Park , David Nimke , Eunjee Cho , Mia Unsworth , Maria Walley , Amber Simpson","doi":"10.1016/j.esmoop.2025.105985","DOIUrl":"10.1016/j.esmoop.2025.105985","url":null,"abstract":"","PeriodicalId":11877,"journal":{"name":"ESMO Open","volume":"11 ","pages":"Article 105985"},"PeriodicalIF":8.3,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147413564","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-02-01Epub Date: 2026-02-28DOI: 10.1016/j.esmoop.2025.105988
An Wang , Yne-Ye Mao , Tao Li , Xin Zhou , Yi-Bing Bai , Tong Zhang , Zhi-Qiang Ma , Yi Hu
{"title":"PP212 Systematic pan-cancer analysis identified NCOA4 as an immunological and prognostic biomarker and validated in lung adenocarcinoma","authors":"An Wang , Yne-Ye Mao , Tao Li , Xin Zhou , Yi-Bing Bai , Tong Zhang , Zhi-Qiang Ma , Yi Hu","doi":"10.1016/j.esmoop.2025.105988","DOIUrl":"10.1016/j.esmoop.2025.105988","url":null,"abstract":"","PeriodicalId":11877,"journal":{"name":"ESMO Open","volume":"11 ","pages":"Article 105988"},"PeriodicalIF":8.3,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147426550","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
扫码关注我们
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号